OOIR: Observatory of International Research

Papers

(The H4-Index of JACC-Cardiovascular Interventions is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Drug-Coated Balloons for Coronary Artery Disease	214
3-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation	155
Alignment of Transcatheter Aortic-Valve Neo-Commissures (ALIGN TAVR)	140
Indigo Aspiration System for Treatment of Pulmonary Embolism	140
5-Year Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves	125
Incidence, Predictors, and Implications of Permanent Pacemaker Requirement After Transcatheter Aortic Valve Replacement	122
Coronary Cannulation After Transcatheter Aortic Valve Replacement	118
Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System	115
ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION)	109
Assessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease	102
Distal Radial Artery Approach to Prevent Radial Artery Occlusion Trial	94
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy	90
Drug-Coated Balloon Versus Drug-Eluting Stent for Small Coronary Vessel Disease	87
Valve-in-Valve Transcatheter Aortic Valve Replacement Versus Redo Surgical Aortic Valve Replacement	85
Transcatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Aortic Valves From the STS/ACC TVT Registry	83
Early Multinational Experience of Transcatheter Tricuspid Valve Replacement for Treating Severe Tricuspid Regurgitation	81
Principles of Intravascular Lithotripsy for Calcific Plaque Modification	80
Clinical Outcomes Following Coronary Bifurcation PCI Techniques	80
Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation	79
Reoperation After Transcatheter Aortic Valve Replacement	79
Randomized Trial Comparing Standard Versus Ultrasound-Assisted Thrombolysis for Submassive Pulmonary Embolism	77
Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Bicuspid Aortic Valve Stenosis	76
Randomized Comparison of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients	73
Patient-Specific Implantation Technique to Obtain Neo-Commissural Alignment With Self-Expanding Transcatheter Aortic Valves	72
Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement	72

Cardiopulmonary Hemodynamic Profile Predicts Mortality After Transcatheter Tricuspid Valve Repair in Chronic Heart Failure	72
Long-Term Outcomes of Coronary Stenting With and Without Use of Intravascular Ultrasound	71
Impact of Left Ventricular Outflow Tract Calcification on Procedural Outcomes After Transcatheter Aortic Valve Replacement	70
COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation	70
Suture- or Plug-Based Large-Bore Arteriotomy Closure	70
Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD	69
Intravascular Lithotripsy for Treatment of Calcified Coronary Lesions	69
Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes	68
Surgical Explantation After TAVR Failure	68
Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization	67
Clinical Outcomes Associated With Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation	67
Intravascular Lithotripsy for Peripheral Artery Calcification	65
Permanent Pacemaker Reduction Using Cusp-Overlapping Projection in TAVR	65
Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the COVID-19 Pandemic	64
Transcatheter Edge-to-Edge Mitral Valve Repair With the MitraClip G4 System	64
Risk of Coronary Obstruction Due to Sinus Sequestration in Redo Transcatheter Aortic Valve Replacement	64
Arterial Lactate in Cardiogenic Shock	63
Coronary Access After TAVR-in-TAVR as Evaluated by Multidetector Computed Tomography	63
The Impact of Coronary Physiology on Contemporary Clinical Decision Making	62
Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement	62
Racial, Ethnic, and Sex Disparities in Patients With STEMI and Cardiogenic Shock	62
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR	61
1-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study	61
Transfemoral Tricuspid Valve Replacement in Patients With Tricuspid Regurgitation	60
Distal or Traditional Transradial Access Site for Coronary Procedures	58
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation	57
6-Month Outcomes of the TricValve System in Patients With Tricuspid Regurgitation	56
Transcatheter Mitral Valve Replacement	56
Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation	56
Early Feasibility Study of Cardioband Tricuspid System for Functional Tricuspid Regurgitation	55
Clinical Characteristics and Outcomes of STEMI Patients With Cardiogenic Shock and Cardiac Arrest	55